Genmab (GMAB) announces topline results for epcoritamab from Phase 3 Epcore dlbcl-1 trial in patients with relapsed/refractory diffuse; said study OS did not reach statistical significance; study demonstrated an overall survival of hr: 0.96
Genmab's announcement regarding the Phase 3 trial results for epcoritamab is significant, as the lack of statistical significance in overall survival may raise concerns about the efficacy of the treatment.
Bayer (BAYN GY) gets Supreme Court review in bid to stop roundup suits, according to reports
Shell (SHEL) and Mitsubishi exploring potential sale of stakes in LNG assets
Genmab (GMAB) announces topline results for epcoritamab from Phase 3 Epcore dlbcl-1 trial in patients with relapsed/refractory diffuse; said study OS did not reach statistical significance; study demonstrated an overall survival of hr: 0.96
NY Fed RRP op demand USD 1.22bln (prev. 2.0bln) across 6 counterparties (prev. 6)
Ukraine President Zelensky says air defences supplies are insufficient and warns of new Russian massive strikes
Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.
While this could lead to a negative reaction in Genmab's share price, the specific hazard ratio of 0.96 suggests that while there is a proliferation of interest in the therapy, it may not translate into a substantial market advantage. This outcome could impact investor sentiment and affect trading in related biopharma stocks as well.
Related headlines
- Situational Awareness builds relationships with new brokers as it attempts rebound, reports FT; is rebuilding large trading positions in stocks such as AMD (AMD), Intel (INTC), SK Hynix (SHY), Sandisk (SNDK) and Coreweave (CRWV)22 hours ago
- Newsquawk Weekly US Earnings Estimates: 14-18th September 2026: LEN the only earning all week19 hours ago
- Corning (GLW) files for a USD 2bln common stock offering of up to USD 2.0bln19 hours ago
- Burry adds to his positions in Zoetis (ZTS) and Lululemon (LULU); sold entire position in Flutter (FLUT)20 hours ago
- Google (GOOGL) just completed its USD 1.5bln-plus deal for AI startup Mechanize, reports Business Insider21 hours ago
- Estee Lauder (EL) reportedly advances against Walmart (WMT) over knockoffs, according to Bloomberg Law22 hours ago
- FanDuel (FLTR) and other sports betting operators are market making on Kalshi, reports Barrons23 hours ago
- Paypal's (PYPL) new chief executive, Enrique Lores, is mapping out his plans for going it alone rather than selling the company for more than USD 50bln, reports WSJ23 hours ago
- AMD (AMD) says Anthropic framework includes purchases of up to 2GW of the MI450 capacity and Co. is shifting from individual chips to a full system, full rack provider23 hours ago
- Tesla (TSLA) says Semi Truck is coming to Europe1 day ago
- GTCR reportedly in talks to purchase software maker SPS Commerce (SPSC)1 day ago
- US EQUITY OPEN: US indices reverse initial CPI losses1 day ago
- Fox's Gasparino says "Paramount’s (PSKY) CEO has "tricks up his sleeve" to get his Warner (WBD) acquisition cleared in California"1 day ago
- Situational Awareness is reportedly active in the options market, according to CNBC citing sources1 day ago
- Chevron (CVX) CEO says early buffers in the oil market have played out and that the price risk from the Iran war is now higher1 day ago
- Daily US Equity Opening News: ORCL gains on earnings and FY guidance beat; ADBE weighed by slight Q4 revenue miss; SMR downgraded1 day ago
- Kroger (KR) executive says food inflation in Q2 was moderately higher than in Q11 day ago
- US PREMARKET MOVERS: ORCL, ADBE, ACVA, KR, RH, CELH, GME, NVO, SMR1 day ago
- US BROKER MOVES: IP upgraded at BofA; NVO downgraded at Morgan Stanley1 day ago
- Kroger (KR) Q2 2026 (USD): Adj. EPS 1.09 (exp. 1.06), revenue 34.6bln (exp. 34.6bln). Cuts SSS outlook 1 day ago
The whole workspace, free to try.
Try it free